SG · Sweetgreen

The thesis

Sweetgreen's recovery from the 2026 cyclospora outbreak is reported fact, and that gives the shares a modest edge over the S&P 500. Comparable sales grew about 5% in October, after a 6.4% decline in the third quarter. Fourth-quarter comparable sales settle whether the rebound lasts. On 5 November 2026, management said it expects growth of about 4% for the quarter.

The shares have given back part of the post-report run but still hold most of it. They closed at $13.36 on 9 November 2026, the highest close of the run, and reached an intraday 52-week high of $13.89 on 10 November 2026. They closed at $12.38 on 12 November 2026, 10.9% below that high. The pullback came on no company news, filing or analyst action beyond a small sale by the chief financial officer on 10 November 2026.

The price already reflects a rebound that holds. At $12.38 on 12 November 2026, the shares sit between the broker targets set since 28 October 2026. Citigroup at $15, Wells Fargo and Oppenheimer at $14, and KeyBanc at $13 are above the close. DA Davidson at $12, TD Cowen at $11 and UBS at $11 are below it. Sweetgreen has not dated the fourth-quarter report. It is expected around late February 2027.

The rating is Medium. The October sales turn and the raised fiscal 2026 outlook are reported, and no fact dated after 5 November 2026 has weakened either. The stretched price limits the edge, because the shares more than doubled within three months.

Bullish and bearish views on Sweetgreen, Inc.

The bull case on Sweetgreen, Inc. (SG), in brief: third-quarter results beat estimates. The bear case: margins remain below last year.

Bull case

• Third-quarter results beat estimates. Revenue of $176.0 million beat the $169.4 million estimate, and the $0.26 loss per share beat the $0.27 estimate, Benzinga reported on 5 November 2026. Same-store sales fell 6.4%, less than the 8.8% consensus decline UBS cited on 28 October 2026.
• Comparable sales turned positive in October. Coverage of the 5 November 2026 earnings call put October comparable sales up about 5%, with transactions up about 4%. Management expects about 4% growth for the fourth quarter, which includes a 1.5 percentage point drag from lapping a one-time gift card benefit.
• The outlook rose above Wall Street models. The 5 November 2026 outlook calls for a fiscal 2026 adjusted EBITDA (earnings before interest, taxes, depreciation and amortization, excluding one-off items) loss of $20–23 million. UBS had modeled a $25.2 million loss on 28 October 2026. Full-year comparable sales guidance improved to a decline of about 5.5%, from a 7.0–8.0% decline in August.
• Six brokers raised targets in one day. On 6 November 2026, Citigroup raised its target to $15 from $13, Wells Fargo to $14 from $11, Oppenheimer to $14, KeyBanc to $13 from $12, DA Davidson to $12 from $5.50 and TD Cowen to $11 from $9, Benzinga and MarketBeat reported.
• The outbreak hit the whole category. Marzetti said on 3 November 2026 that the cyclospora outbreak significantly hurt both its retail and foodservice net sales, Benzinga reported. Sweetgreen's October rebound fits a category-wide shock that is fading.
• Cash cushions the recovery. Cash was $119.8 million on 27 September 2026, up from $89.2 million on 28 December 2025, the 10-Q filed on 6 November 2026 shows. The Spyce sale brought in $100 million in cash and $86.4 million of Wonder Group preferred stock.

Bear case

• Margins remain below last year. Restaurant-level margin fell to 10.4% from 13.1% a year earlier, on lower sales and higher labor costs, the 5 November 2026 release showed. Adjusted EBITDA was a $6.8 million loss, wider than the $4.4 million loss a year earlier.
• Restaurant sales volumes are lower. Average unit volume fell to $2.473 million from $2.769 million a year earlier, the 8-K showed. Traffic fell 4.9% in the third quarter.
• Wraps are pulling down the check. Product mix cut third-quarter comparable sales by 2.1% as guests shifted toward wraps, the release showed. Menu price added only 0.6%.
• Fewer new restaurants in 2027. Sweetgreen expects about half as many net new openings in fiscal 2027 as the roughly 10 planned for fiscal 2026, the 5 November 2026 release said. That leaves growth more dependent on comparable sales.
• The chief financial officer sold near the high. Jamie McConnell sold 4,000 shares on the open market at $13.76 on 10 November 2026, according to an SEC Form 4. That was the day of the 52-week intraday high. He and the chief operating officer also sold shares at $6.21 on 17 August 2026.
• Most covering analysts are neutral or negative. MarketBeat counted 6 Buy, 9 Hold and 3 Sell ratings on 6 November 2026. Three of the seven targets set since 28 October 2026 sit below the $12.38 close of 12 November 2026.

Price setup

The shares closed at $12.38 on 12 November 2026, after $13.36 on 9 November 2026, $13.24 on 10 November 2026 and $12.88 on 11 November 2026. The 52-week intraday high is $13.89 on 10 November 2026, and the 52-week closing low is $4.70 on 27 March 2026. The three-month gain is 97.1%, measured from the $6.28 close on 14 August 2026.

On adjusted daily closes, the 50-day moving average is $9.42 and the 200-day is $7.43 as of 12 November 2026. The price sits well above both. The nearest reference below is the 5 November 2026 close, the session before the after-market release. A close under it would erase the whole post-earnings gain. Above, the 9 November 2026 close of $13.36 and the $13.89 intraday high mark where the run stalled. MarketBeat listed beta at 2.11 on 6 November 2026, so moves of several percent in a session are common.

Catalysts ahead

• ~25 February 2027 (est.): Fourth-quarter 2026 report; date not confirmed by the company. The first full-quarter reading on whether positive comparable sales lasted beyond October, measured against management's roughly 4% growth, plus the first fiscal 2027 outlook.

What would change the view

A daily close below $11.55, the 5 November 2026 close before the third-quarter report, which would erase the post-earnings gain. Separately, fourth-quarter comparable sales below the roughly 4% growth management described, or a fiscal 2026 adjusted EBITDA loss above $23 million.

The risks this note tracks, each with what would confirm it:

• The October rebound fades and fourth-quarter comparable sales miss management's expectation. Confirmed by: fourth-quarter comparable sales below roughly 4% growth, or a lowered outlook at an investor event before the report.
• Sales recover without margin, because labor costs and the shift to wraps absorb the gain. Confirmed by: fiscal 2026 restaurant-level margin below the 11.0–11.5% range, or an adjusted EBITDA loss above $23 million.
• Analysts and insiders treat the price as full after the shares more than doubled in three months. Confirmed by: target cuts or downgrades from the firms that raised on 6 November 2026, or further open-market sales by officers in SEC Form 4 filings.
• Slower unit openings reduce revenue growth in 2027. Confirmed by: fiscal 2027 guidance whose revenue growth relies on comparable sales, with net new openings at or below about half the fiscal 2026 count.
• A new leafy-green contamination event hits traffic again. Confirmed by: a public health notice or supplier recall tied to Sweetgreen's produce supply chain.

What it trades with

Sweetgreen trades with fast-casual restaurant stocks and consumer discretionary sentiment, and its beta of 2.11 (MarketBeat, 6 November 2026) amplifies those moves. The cyclospora outbreak drove both the 2026 fall and the rebound, and it also hit salad supplier Marzetti's sales (Benzinga, 3 November 2026). A shared produce-safety headline would likely move both. Fiscal 2026 GAAP earnings include a $160.5 million gain on the Spyce disposal. Screens built on reported earnings therefore misstate the operating trend.